0
Original Research: Diffuse Lung Disease |

The Impact of Lung Cancer on Survival of Idiopathic Pulmonary FibrosisLung Cancer and Idiopathic Pulmonary Fibrosis

Sara Tomassetti, MD; Christian Gurioli, MD; Jay H. Ryu, MD, FCCP; Paul A. Decker, MS; Claudia Ravaglia, MD; Paola Tantalocco, BME; Matteo Buccioli, BME; Sara Piciucchi, MD; Nicola Sverzellati, MD; Alessandra Dubini, MD; Giampaolo Gavelli, MD; Marco Chilosi, MD; Venerino Poletti, MD, FCCP
Author and Funding Information

From the Department of Diseases of the Thorax (Drs Tomassetti, Gurioli, Ravaglia, Tantalocco, Buccioli, and Poletti), G. B. Morgagni Hospital, Forlì, Italy; Division of Pulmonary and Critical Care Medicine (Dr Ryu) and Biomedical Statistics and Informatics (Mr Decker), Mayo Clinic, Mayo Foundation for Medical Education and Research, Rochester, MN; Department of Radiology (Dr Piciucchi), G. B. Morgagni Hospital, Forlì, Italy; Department of Radiology (Dr Sverzellati), Parma University, Parma, Italy; Department of Pathology (Dr Dubini), G. B. Morgagni Hospital, Forlì, Italy; and Department of Radiology (Dr Gavelli), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (Istituto di Ricovero e Cura a Carattere Scientifico), Meldola (Forlì), and Department of Pathology (Dr Chilosi), Verona University, Verona, Italy.

CORRESPONDENCE TO: Venerino Poletti, MD, FCCP, U. O. Pneumologia, G. B. Morgagni Hospital, Via C. Forlanini 34, 47100 Forlì (FC), Italy; e-mail: venerino.poletti@gmail.com


Drs Tomassetti and Gurioli contributed equally.

Part of this article was presented at the ERS Annual Congress, September 24-28, 2011, Amsterdam, The Netherlands.

FUNDING/SUPPORT: This study was supported by Associazione Morgagni per le Malattie Polmonari (AMMP).

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.


Chest. 2015;147(1):157-164. doi:10.1378/chest.14-0359
Text Size: A A A
Published online

BACKGROUND:  Lung cancer (LC) is frequently associated with idiopathic pulmonary fibrosis (IPF). Despite this well-known association, the outcome of LC in patients with IPF is unclear. The objective of this study was to evaluate the impact of LC on survival of patients with associated IPF.

METHODS:  A total of 260 patients with IPF were reviewed, and 186 IPF cases had complete clinical and follow-up data. Among these, five cases were excluded because LC was radiologically suspected but not histologically proven. The remaining 181 cases were categorized in two groups: 23 patients with biopsy-proven LC and IPF (LC-IPF) and 158 patients with IPF only (IPF). Survival and clinical characteristics of the two groups were compared.

RESULTS:  Prevalence of histologically proven LC was 13%, and among those with LC-IPF cumulative incidence at 1 and 3 years was 41% and 82%. Patients with LC were more frequently smokers (91.3% vs 71.6%, P = .001), with combined pulmonary fibrosis and emphysema (52% vs 32%, P = .052). Survival in patients with LC-IPF was significantly worse than in patients with IPF without LC (median survival, 38.7 months vs 63.9 months; hazard ratio = 5.0; 95% CI, 2.91-8.57; P < .001). Causes of death in the study group were respiratory failure in 43% of patients, LC progression in 13%, and LC treatment-related complications in 17%.

CONCLUSIONS:  In patients with IPF, LC has a significant adverse impact on survival. Diagnosis and treatment of LC in IPF are burdened by an increased incidence of severe complicating events, apparently as lethal as the cancer itself.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
Idiopathic Pulmonary Fibrosis*: Challenges and Opportunities for the Clinician and Investigator
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543